=== SEC Form 4 — Statement of Changes in Beneficial Ownership ===
Document Type: 4
Period of Report: 2026-08-06
10b5-1 Pre-arranged Plan: No
--- Issuer ---
Name: Merck & Co., Inc. (MRK)
CIK: 0000310158
--- Reporting Owner ---
Name: DeLuca Richard R.
CIK: 0001421339
Role: Officer (EVP&Pres, Merck Animal Heallth)
--- Non-Derivative Transactions ---
[Transaction #1]
Security: Common Stock
Date: 2026-08-06 | Code: S (Open market sale)
Shares: -805 | Price: $131.02
Total Value: $105,472.39
Shares Owned After: 160,732.07 | Ownership: D (Direct)
Footnotes:
[F1] The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
[Transaction #2]
Security: Common Stock
Date: 2026-08-06 | Code: S (Open market sale)
Shares: -4,945 | Price: $130.23
Total Value: $643,993.28
Shares Owned After: 155,787.07 | Ownership: D (Direct)
Footnotes:
[F2] The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.0000 to $130.9200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
[Transaction #3]
Security: Common Stock
Date: 2026-08-06 | Code: S (Open market sale)
Shares: -300 | Price: $131.02
Total Value: $39,306.99
Shares Owned After: 155,487.07 | Ownership: D (Direct)
Footnotes:
[F3] The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.0300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
--- Footnotes (Complete Index) ---
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.0000 to $130.9200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.0300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
--- Signature ---
/s/ /s/ Kelly E. W. Grez as Attorney-in-Fact for Richard R. DeLuca, Jr. (2026-08-10)
